drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
CD19-directed chimeric antigen receptor T-cell therapy (engineered autologous T cells) administered intravenously in split doses; recognizes CD19 and, via CAR signaling, activates cytotoxicity to kill malignant B cells, resulting in B-cell depletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a CD19-specific chimeric antigen receptor recognize CD19 on B-lineage malignant cells; CAR signaling activates T-cell cytotoxicity and cytokine release, leading to targeted lysis and depletion of CD19+ cells.
drug_name
ssCART-19
nct_id_drug_ref
NCT06367114